1. The administration of angiotensin II among patients with refractory shock was associated with improved hemodynamic stability and decreased total vasopressor requirement at three hours.
Evidence Level Rating: 2 (Good)
Vasodilatory shock that is refractory to catecholamine- and arginine-based vasopressors is common in critical illness and associated with significant mortality, often...
1. Angiotensin-converting-enzyme (ACE) inhibitors had been shown to significantly reduce mortality in patients with heart failure, and it was hypothesized that adding an angiotensin-receptor blocker (ARB) would provide further clinical benefit.
2. The addition of candesartan to ACE inhibitor treatment led to significant reductions in cardiovascular mortality and hospitalization for...
1. LCZ696 is a novel drug that combines the neprilysin inhibitor, sacubitril, and the angiotensin receptor blocker (ARB), valsartan.
2. In patients with heart failure with reduced ejection fraction, LCZ696 was more effective than enalapril in preventing cardiovascular death and hospitalization.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Over 6 million Americans...
1. Candesartan significantly reduced cardiovascular death and hospital admission for chronic heart failure in patients with heart failure and reduced ventricular function, who were intolerant to ACE inhibitors.
2. Candesartan was well-tolerated in patients with previous intolerance to ACE inhibitors.
Original Date of Publication: September 6, 2003
Study Rundown: Angiotensin-converting-enzyme (ACE) inhibitors have...